Molecular therapeutics: 21st century medicine
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Chichester
Wiley
2007
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Includes index |
| Beschreibung: | X, 251 S. Ill., graph. Darst. |
| ISBN: | 9780470019177 9780470019160 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV023360759 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 080624s2007 ad|| |||| 00||| eng d | ||
| 010 | |a 2007028135 | ||
| 020 | |a 9780470019177 |c pbk. : alk. paper |9 978-0-470-01917-7 | ||
| 020 | |a 9780470019160 |c hardback : alk. paper |9 978-0-470-01916-0 | ||
| 024 | 3 | |a 9780470019177 | |
| 035 | |a (OCoLC)148710786 | ||
| 035 | |a (DE-599)BSZ275052656 | ||
| 040 | |a DE-604 |b ger | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-578 | ||
| 050 | 0 | |a RB155.8 | |
| 082 | 0 | |a 616/.042 |2 22 | |
| 084 | |a VT 5200 |0 (DE-625)147743:253 |2 rvk | ||
| 084 | |a QU 560 |2 nlm | ||
| 100 | 1 | |a Greenwell, Pamela |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Molecular therapeutics |b 21st century medicine |c Pamela Greenwell ; Michelle McCulley |
| 264 | 1 | |a Chichester |b Wiley |c 2007 | |
| 300 | |a X, 251 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Includes index | ||
| 650 | 7 | |a Gentherapie |2 swd | |
| 650 | 7 | |a Gentransfer |2 swd | |
| 650 | 4 | |a Génétique moléculaire | |
| 650 | 7 | |a Molekulargenetik |2 swd | |
| 650 | 4 | |a Thérapie génique | |
| 650 | 4 | |a Gene therapy | |
| 650 | 4 | |a Molecular genetics | |
| 650 | 4 | |a Gene Therapy / Popular Works | |
| 650 | 4 | |a Gene Therapy / Popular Works / ethics | |
| 650 | 4 | |a Gene Transfer Techniques / Popular Works | |
| 650 | 4 | |a Molecular Biology / Popular Works | |
| 650 | 0 | 7 | |a Molekulare Medizin |0 (DE-588)4543844-4 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Molekulare Medizin |0 (DE-588)4543844-4 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a McCulley, Michelle |e Verfasser |4 aut | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016544219&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016544219 | ||
Datensatz im Suchindex
| _version_ | 1804137723398717441 |
|---|---|
| adam_text | Contents
Prologue xi
1 Introduction 1
1.1 Microbial diseases 2
1.2 Cancer and heart disease 3
1.2.1 Cancer 4
1.2.2 Heart disease 5
1.3 Genetic diseases 5
1.3.1 Dominant diseases 6
1.3.2 Recessive diseases 6
1.4 Role of molecular biology in therapeutics 7
2 Prenatal diagnosis and pre-implantation 11
2.1 Should we treat inherited diseases? 11
2.2 Genetic screening 12
2.2.1 Pre-implementation genetic diagnosis 13
2.3 Counselling 15
3 Simple protein replacement therapy 17
3.1 Preventing transfusion-transmissible infectious
diseases in the UK 18
3.2 Ensuring the safety of organ transplants 19
3.3 Preventing transfusion-transmissible infectious
diseases worldwide 20
3.4 HTV 20
4 Recombinant protein production 23
4.1 Choice of organism 23
4.1.1 Somatostatin: an example of protein produced
in E. coli 27
4.1.2 Insulin: an example of a recombinant protein 27
4.2 Alternatives to E. coli for the production of
recombinant proteins 29
4.2.1 Insect cells 29
4.2.2 Whole insects 30
4.2.3 Mammalian cells 30
vi CONTENTS
4.2.4 Plants 30
4.2.5 Transgenic animals 31
4.3 Problems with recombinant protein production 31
4.3.1 Problems with glycosylation 32
4.3.2 Effect of glycosylation 33
4.3.3 Erythropoietin: an example of protein produced
in mammalian cells 35
4.3.4 Production method 36
4.3.5 Preparation of Factor VIII 36
4.3.6 Transgenic pigs and Factor VIII 37
4.4 All recombinants must be tested before they are
given to humans 38
4.5 Why make recombinant proteins? 39
4.6 Recombinant products 40
4.7 Generics 40
5 Recombinant vaccines 43
5.1 Vaccine history 43
5.2 Vaccines 45
5.3 Vaccine methods 46
5.4 Types of vaccine 47
5.5 The limitations of vaccine programmes 48
5.6 The role of the WHO 50
5.7 Problems specific to developing countries 51
5.8 Economics and logistics of vaccinology 52
5.9 Recombinant vaccines 54
5.9.1 Simple recombinant protein vaccines 55
5.9.2 Gene vaccines: the vaccinia virus approach 57
5.9.3 DNA vaccines 57
5.9.4 Edible vaccines from transgenic plants 58
5.10 Rational design: bioinformatics and proteomics 59
5.11 Other interesting areas for vaccine development 60
5.12 Conclusion 60
6 Therapeutic antibodies and immunotherapy 63
6.1 Monoclonal antibodies 63
6.2 Monoclonal production 64
6.3 Therapeutic monoclonal antibodies 66
6.3.1 Human monoclonals 66
6.3.2 Humanised antibodies 67
6.4 Transgenic monoclonals 69
6.5 The uses of monoclonal antibodies in therapy 69
6.6 Specific examples of therapeutic strategies 70
6.6.1 Unconjugated antibodies - treatment of
kidney rejection 70
6.6.2 HIV treatment 71
6.6.3 Cancer therapy and monoclonal antibodies 71
6.6.4 Herceptin in breast cancer therapy 71
CONTENTS vii
6.6.5 Treatment of multi-drug-resistant cancer cells 72
6.6.6 Anti-endotoxin antibodies 73
6.6.7 Conjugated antibodies 73
6.6.8 Delivery of radionuclides to leukaemia and
lymphoma patients 74
6.6.9 Drug delivery 74
6.6.10 Toxin delivery 75
6.6.11 Bispecific antibodies 75
6.7 Other recombinant proteins used in immunotherapy 76
6.7.1 Cytokines 76
6.7.2 Colony-stimulating factors and growth factors 79
7 Transgenic animals 83
7.1 Why do we want to engineer the genomes of animals? 83
7.2 Experimental procedure 85
7.2.1 Method 1: Germline manipulation 85
7.2.2 Method 2: Using embryonic stem cells 87
7.3 DNA constructs, insertional mutagenesis and
homologous recombination 90
7.4 Uses of inducible and tissue-specific promoters 91
7.5 Introduction of the DNA into the cells 92
7.6 Uses of transgenics 93
7.6.1 Recombinant protein production 93
7.6.2 Animal models of human diseases 94
8 Transplantation: a form of gene therapy 99
8.1 Introduction 99
8.2 Bone marrow 100
8.2.1 Logistical problems with BMT 102
8.3 Solid organ transplantation 102
8.3.1 Heart transplantation 103
8.3.2 Lung 104
8.3.3 Kidney 105
8.3.4 Liver 105
8.3.5 Ovarian tissue 106
8.4 Other cells and tissues 106
8.5 Summary of the problems associated
with transplantation 107
8.6 Transplantation statistics 108
8.7 Legislation 108
8.8 Religious beliefs and transplantation 110
9 Xeno transplantation 113
9.1 Introduction 113
9.2 Rationale for the use of non-human donors 114
9.3 Organs from non-human primates 114
9.4 Pigs 115
9.4.1 Can we pretreat the recipient to prevent rejection? 116
viii CONTENTS
9.5 Problems with pigs 117
9.5.1 Will pig hearts function in humans? 117
9.5.2 Xenozoonoses 117
9.5.3 Religious objections 118
9.5.4 Animal activists 119
9.6 Government legislation 119
9.7 When will xenotransplantation start? 120
9.8 Patient attitudes 120
9.9 Ethics 121
9.10 Alternatives to xenotransplants 121
10 Reproductive cloning 125
10.1 History 125
10.2 Problems 127
10.3 Why was there so much interest in Dolly? 128
10.4 Was Dolly a lone example? 129
10.5 Why is cloning useful? 129
10.6 Is human cloning a reality? 130
10.7 Why can we not produce human clones that
are identical? 131
10.8 So why clone humans? 132
10.9 What are the ethical and moral problems? 132
11 Stem cell therapy 137
11.1 The potency of cells 137
11.2 Cloning 137
11.3 Potency of stem cells 138
11.4 Potential sources of stem cells 138
11.5 Stem cells and therapeutic cloning 138
11.6 Legislation and therapeutic cloning 140
11.7 Other sources of stem cells 142
11.8 What can be done? 142
11.9 Experiments on embryonic cells 143
11.10 Experiments on fetal tissue and cord blood 143
11.11 Stem cells from adult tissues 143
11.12 Safety and technical problems 144
11.13 Perceived scope of therapy 145
11.14 Clinical trials of stem cell therapy 145
11.15 What are the future prospects for stem cell research? 146
12 Gene augmentation therapy 149
12.1 Introduction 149
12.2 Strategy 150
12.2.1 DNA delivery 151
12.2.2 Viral vectors and gene therapy 152
12.2.3 Artificial viruses 155
CONTENTS ix
12.2.4 Non-viral delivery in gene therapy 155
12.2.5 What tissues can we currently target? 157
12.2.6 Targeting gene expression 159
12.2.7 Problems associated with augmentation therapy 160
12.2.8 Gene augmentation therapy vs. recombinant
DNA therapy or transplantation 161
12.2.9 Current criteria for the use of gene therapy 162
12.2.10 The bystander effect 163
12.2.11 Candidates for gene therapy 163
13 Gene therapy trials for inherited diseases 165
13.1 Introduction 165
13.2 Examples of disease treated with retro viral
gene therapy 166
13.2.1 Severe combined immunodeficiency 166
13.2.2 Hypercholesterolaemia 169
13.3 Cystic fibrosis 170
13.3.1 Rationale for adenoviral vectors 171
13.3.2 Early animal trials 171
13.3.3 Is CF gene therapy safe but not useful ? 172
13.3.4 Problems also found in in vivo delivery 172
13.4 Animal trials with Factor IX 173
13.5 Adenoviruses have also been used to introduce genes
into brain 174
13.6 Duchenne s muscular dystrophy 175
13.7 Problems with adenoviruses 175
13.8 The uses of adeno-associated viruses 176
13.8.1 Haemophilia B treatment with Factor IX
gene augmentation 176
13.8.2 AAV therapy for DMD 177
13.9 Liposome vector trials 178
13.10 Trials with polymer mareix delivery 178
14 Gene silencing technologies 181
14.1 Antisense therapy 181
14.1.1 Modification of antisense molecules 183
14.1.2 Replacement of oxygens in the phosphate bridge 184
14.1.3 Modifications can be made to the bases themselves 184
14.1.4 Other types of modifications 185
14.1.5 The ideal oligonucleotide 185
14.1.6 Uptake 185
14.1.7 Uses of antisense oligonucleotides 187
14.1.8 Examples 187
14.1.9 Catalytic antisense molecules 191
14.2 Triple helix (triplex) technology 191
14.2.1 Problems 193
14.2.2 Advantages over antisense strategies 193
14.2.3 Experimental data 194
x CONTENTS
14.3 Ribozymes 196
14.3.1 Examples of ribozyme therapies 197 !
14.4 Small interfering RNAs (siRNAs) 198
14.4.1 Clinical trials and siRNA 202
14.4.2 Is RNAi better than antisense? 202 ,
15 Gene therapy for cancer 205
15.1 What causes cancer? 205
15.2 Cancer: a multifactorial disease 206
15.3 Cancer statistics 207
15.4 Best treatment currently available 208
15.4.1 Avoidance 208
15.4.2 Screening 208
15.4.3 Surgery 209
15.4.4 Chemotherapy 209
15.4.5 Radiotherapy 210
15.5 Do chemo- and radiotherapy cause problems? 210
15.6 New cancer therapies 210
15.7 Cancer models in animals 211
15.8 What kinds of gene therapy can we use to
treat cancer? 212
15.9 Perceived problems in cancer gene
augmentation therapy 213
15.9.1 Killing cells with ganciclovir or suicide therapy 213
15.9.2 Prodrug activation therapy 214
15.9.3 Enhancing the immune system with gene therapy 215
15.10 Gene silencing technologies and cancer 217
15.11 Conclusion 219
16 Single-nucleotide polymorphisms (SNPs)
and therapy 223
17 Legislation, clinical trials and ethical issues 231
17.1 Legislative bodies 231
17.2 Clinical trials 233
17.3 The problems of placebo controlled trials 236
17.4 The need for informed consent 238
17.5 Trials in developing countries 239
17.6 Recent trial issues 241
17.7 Conclusion 242
Epilogue 245
Sourcing references 245
Index 247
|
| adam_txt |
Contents
Prologue xi
1 Introduction 1
1.1 Microbial diseases 2
1.2 Cancer and heart disease 3
1.2.1 Cancer 4
1.2.2 Heart disease 5
1.3 Genetic diseases 5
1.3.1 Dominant diseases 6
1.3.2 Recessive diseases 6
1.4 Role of molecular biology in therapeutics 7
2 Prenatal diagnosis and pre-implantation 11
2.1 Should we treat inherited diseases? 11
2.2 Genetic screening 12
2.2.1 Pre-implementation genetic diagnosis 13
2.3 Counselling 15
3 Simple protein replacement therapy 17
3.1 Preventing transfusion-transmissible infectious
diseases in the UK 18
3.2 Ensuring the safety of organ transplants 19
3.3 Preventing transfusion-transmissible infectious
diseases worldwide 20
3.4 HTV 20
4 Recombinant protein production 23
4.1 Choice of organism 23
4.1.1 Somatostatin: an example of protein produced
in E. coli 27
4.1.2 Insulin: an example of a recombinant protein 27
4.2 Alternatives to E. coli for the production of
recombinant proteins 29
4.2.1 Insect cells 29
4.2.2 Whole insects 30
4.2.3 Mammalian cells 30
vi CONTENTS
4.2.4 Plants 30
4.2.5 Transgenic animals 31
4.3 Problems with recombinant protein production 31
4.3.1 Problems with glycosylation 32
4.3.2 Effect of glycosylation 33
4.3.3 Erythropoietin: an example of protein produced
in mammalian cells 35
4.3.4 Production method 36
4.3.5 Preparation of Factor VIII 36
4.3.6 Transgenic pigs and Factor VIII 37
4.4 All recombinants must be tested before they are
given to humans 38
4.5 Why make recombinant proteins? 39
4.6 Recombinant products 40
4.7 Generics 40
5 Recombinant vaccines 43
5.1 Vaccine history 43
5.2 Vaccines 45
5.3 Vaccine methods 46
5.4 Types of vaccine 47
5.5 The limitations of vaccine programmes 48
5.6 The role of the WHO 50
5.7 Problems specific to developing countries 51
5.8 Economics and logistics of vaccinology 52
5.9 Recombinant vaccines 54
5.9.1 Simple recombinant protein vaccines 55
5.9.2 Gene vaccines: the vaccinia virus approach 57
5.9.3 DNA vaccines 57
5.9.4 Edible vaccines from transgenic plants 58
5.10 Rational design: bioinformatics and proteomics 59
5.11 Other interesting areas for vaccine development 60
5.12 Conclusion 60
6 Therapeutic antibodies and immunotherapy 63
6.1 Monoclonal antibodies 63
6.2 Monoclonal production 64
6.3 Therapeutic monoclonal antibodies 66
6.3.1 Human monoclonals 66
6.3.2 Humanised antibodies 67
6.4 Transgenic monoclonals 69
6.5 The uses of monoclonal antibodies in therapy 69
6.6 Specific examples of therapeutic strategies 70
6.6.1 Unconjugated antibodies - treatment of
kidney rejection 70
6.6.2 HIV treatment 71
6.6.3 Cancer therapy and monoclonal antibodies 71
6.6.4 Herceptin in breast cancer therapy 71
CONTENTS vii
6.6.5 Treatment of multi-drug-resistant cancer cells 72
6.6.6 Anti-endotoxin antibodies 73
6.6.7 Conjugated antibodies 73
6.6.8 Delivery of radionuclides to leukaemia and
lymphoma patients 74
6.6.9 Drug delivery 74
6.6.10 Toxin delivery 75
6.6.11 Bispecific antibodies 75
6.7 Other recombinant proteins used in immunotherapy 76
6.7.1 Cytokines 76
6.7.2 Colony-stimulating factors and growth factors 79
7 Transgenic animals 83
7.1 Why do we want to engineer the genomes of animals? 83
7.2 Experimental procedure 85
7.2.1 Method 1: Germline manipulation 85
7.2.2 Method 2: Using embryonic stem cells 87
7.3 DNA constructs, insertional mutagenesis and
homologous recombination 90
7.4 Uses of inducible and tissue-specific promoters 91
7.5 Introduction of the DNA into the cells 92
7.6 Uses of transgenics 93
7.6.1 Recombinant protein production 93
7.6.2 Animal models of human diseases 94
8 Transplantation: a form of gene therapy 99
8.1 Introduction 99
8.2 Bone marrow 100
8.2.1 Logistical problems with BMT 102
8.3 Solid organ transplantation 102
8.3.1 Heart transplantation 103
8.3.2 Lung 104
8.3.3 Kidney 105
8.3.4 Liver 105
8.3.5 Ovarian tissue 106
8.4 Other cells and tissues 106
8.5 Summary of the problems associated
with transplantation 107
8.6 Transplantation statistics 108
8.7 Legislation 108
8.8 Religious beliefs and transplantation 110
9 Xeno transplantation 113
9.1 Introduction 113
9.2 Rationale for the use of non-human donors 114
9.3 Organs from non-human primates 114
9.4 Pigs 115
9.4.1 Can we pretreat the recipient to prevent rejection? 116
viii CONTENTS
9.5 Problems with pigs 117
9.5.1 Will pig hearts function in humans? 117
9.5.2 Xenozoonoses 117
9.5.3 Religious objections 118
9.5.4 Animal activists 119
9.6 Government legislation 119
9.7 When will xenotransplantation start? 120
9.8 Patient attitudes 120
9.9 Ethics 121
9.10 Alternatives to xenotransplants 121
10 Reproductive cloning 125
10.1 History 125
10.2 Problems 127
10.3 Why was there so much interest in Dolly? 128
10.4 Was Dolly a lone example? 129
10.5 Why is cloning useful? 129
10.6 Is human cloning a reality? 130
10.7 Why can we not produce human clones that
are identical? 131
10.8 So why clone humans? 132
10.9 What are the ethical and moral problems? 132
11 Stem cell therapy 137
11.1 The potency of cells 137
11.2 Cloning 137
11.3 Potency of stem cells 138
11.4 Potential sources of stem cells 138
11.5 Stem cells and therapeutic cloning 138
11.6 Legislation and therapeutic cloning 140
11.7 Other sources of stem cells 142
11.8 What can be done? 142
11.9 Experiments on embryonic cells 143
11.10 Experiments on fetal tissue and cord blood 143
11.11 Stem cells from adult tissues 143
11.12 Safety and technical problems 144
11.13 Perceived scope of therapy 145
11.14 Clinical trials of stem cell therapy 145
11.15 What are the future prospects for stem cell research? 146
12 Gene augmentation therapy 149
12.1 Introduction 149
12.2 Strategy 150
12.2.1 DNA delivery 151
12.2.2 Viral vectors and gene therapy 152
12.2.3 Artificial viruses 155
CONTENTS ix
12.2.4 Non-viral delivery in gene therapy 155
12.2.5 What tissues can we currently target? 157
12.2.6 Targeting gene expression 159
12.2.7 Problems associated with augmentation therapy 160
12.2.8 Gene augmentation therapy vs. recombinant
DNA therapy or transplantation 161
12.2.9 Current criteria for the use of gene therapy 162
12.2.10 The bystander effect 163
12.2.11 Candidates for gene therapy 163
13 Gene therapy trials for inherited diseases 165
13.1 Introduction 165
13.2 Examples of disease treated with retro viral
gene therapy 166
13.2.1 Severe combined immunodeficiency 166
13.2.2 Hypercholesterolaemia 169
13.3 Cystic fibrosis 170
13.3.1 Rationale for adenoviral vectors 171
13.3.2 Early animal trials 171
13.3.3 Is CF gene therapy 'safe but not useful'? 172
13.3.4 Problems also found in in vivo delivery 172
13.4 Animal trials with Factor IX 173
13.5 Adenoviruses have also been used to introduce genes
into brain 174
13.6 Duchenne's muscular dystrophy 175
13.7 Problems with adenoviruses 175
13.8 The uses of adeno-associated viruses 176
13.8.1 Haemophilia B treatment with Factor IX
gene augmentation 176
13.8.2 AAV therapy for DMD 177
13.9 Liposome vector trials 178
13.10 Trials with polymer mareix delivery 178
14 Gene silencing technologies 181
14.1 Antisense therapy 181
14.1.1 Modification of antisense molecules 183
14.1.2 Replacement of oxygens in the phosphate bridge 184
14.1.3 Modifications can be made to the bases themselves 184
14.1.4 Other types of modifications 185
14.1.5 The ideal oligonucleotide 185
14.1.6 Uptake 185
14.1.7 Uses of antisense oligonucleotides 187
14.1.8 Examples 187
14.1.9 Catalytic antisense molecules 191
14.2 Triple helix (triplex) technology 191
14.2.1 Problems 193
14.2.2 Advantages over antisense strategies 193
14.2.3 Experimental data 194
x CONTENTS
14.3 Ribozymes 196
14.3.1 Examples of ribozyme therapies 197 !
14.4 Small interfering RNAs (siRNAs) 198
14.4.1 Clinical trials and siRNA 202
14.4.2 Is RNAi better than antisense? 202 ,
15 Gene therapy for cancer 205
15.1 What causes cancer? 205
15.2 Cancer: a multifactorial disease 206
15.3 Cancer statistics 207
15.4 Best treatment currently available 208
15.4.1 Avoidance 208
15.4.2 Screening 208
15.4.3 Surgery 209
15.4.4 Chemotherapy 209
15.4.5 Radiotherapy 210
15.5 Do chemo- and radiotherapy cause problems? 210
15.6 New cancer therapies 210
15.7 Cancer models in animals 211
15.8 What kinds of gene therapy can we use to
treat cancer? 212
15.9 Perceived problems in cancer gene
augmentation therapy 213
15.9.1 Killing cells with ganciclovir or suicide therapy 213
15.9.2 Prodrug activation therapy 214
15.9.3 Enhancing the immune system with gene therapy 215
15.10 Gene silencing technologies and cancer 217
15.11 Conclusion 219
16 Single-nucleotide polymorphisms (SNPs)
and therapy 223
17 Legislation, clinical trials and ethical issues 231
17.1 Legislative bodies 231
17.2 Clinical trials 233
17.3 The problems of placebo controlled trials 236
17.4 The need for informed consent 238
17.5 Trials in developing countries 239
17.6 Recent trial issues 241
17.7 Conclusion 242
Epilogue 245
Sourcing references 245
Index 247 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Greenwell, Pamela McCulley, Michelle |
| author_facet | Greenwell, Pamela McCulley, Michelle |
| author_role | aut aut |
| author_sort | Greenwell, Pamela |
| author_variant | p g pg m m mm |
| building | Verbundindex |
| bvnumber | BV023360759 |
| callnumber-first | R - Medicine |
| callnumber-label | RB155 |
| callnumber-raw | RB155.8 |
| callnumber-search | RB155.8 |
| callnumber-sort | RB 3155.8 |
| callnumber-subject | RB - Pathology |
| classification_rvk | VT 5200 |
| ctrlnum | (OCoLC)148710786 (DE-599)BSZ275052656 |
| dewey-full | 616/.042 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616/.042 |
| dewey-search | 616/.042 |
| dewey-sort | 3616 242 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| discipline_str_mv | Chemie / Pharmazie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01947nam a2200541 c 4500</leader><controlfield tag="001">BV023360759</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">080624s2007 ad|| |||| 00||| eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a">2007028135</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780470019177</subfield><subfield code="c">pbk. : alk. paper</subfield><subfield code="9">978-0-470-01917-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780470019160</subfield><subfield code="c">hardback : alk. paper</subfield><subfield code="9">978-0-470-01916-0</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9780470019177</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)148710786</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BSZ275052656</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RB155.8</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616/.042</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VT 5200</subfield><subfield code="0">(DE-625)147743:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QU 560</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Greenwell, Pamela</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular therapeutics</subfield><subfield code="b">21st century medicine</subfield><subfield code="c">Pamela Greenwell ; Michelle McCulley</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Chichester</subfield><subfield code="b">Wiley</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">X, 251 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes index</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gentherapie</subfield><subfield code="2">swd</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gentransfer</subfield><subfield code="2">swd</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Génétique moléculaire</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Molekulargenetik</subfield><subfield code="2">swd</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thérapie génique</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gene therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular genetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gene Therapy / Popular Works</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gene Therapy / Popular Works / ethics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gene Transfer Techniques / Popular Works</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular Biology / Popular Works</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Molekulare Medizin</subfield><subfield code="0">(DE-588)4543844-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Molekulare Medizin</subfield><subfield code="0">(DE-588)4543844-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McCulley, Michelle</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016544219&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016544219</subfield></datafield></record></collection> |
| id | DE-604.BV023360759 |
| illustrated | Illustrated |
| index_date | 2024-07-02T21:09:03Z |
| indexdate | 2024-07-09T21:16:50Z |
| institution | BVB |
| isbn | 9780470019177 9780470019160 |
| language | English |
| lccn | 2007028135 |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016544219 |
| oclc_num | 148710786 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-578 |
| owner_facet | DE-19 DE-BY-UBM DE-578 |
| physical | X, 251 S. Ill., graph. Darst. |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Wiley |
| record_format | marc |
| spelling | Greenwell, Pamela Verfasser aut Molecular therapeutics 21st century medicine Pamela Greenwell ; Michelle McCulley Chichester Wiley 2007 X, 251 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Includes index Gentherapie swd Gentransfer swd Génétique moléculaire Molekulargenetik swd Thérapie génique Gene therapy Molecular genetics Gene Therapy / Popular Works Gene Therapy / Popular Works / ethics Gene Transfer Techniques / Popular Works Molecular Biology / Popular Works Molekulare Medizin (DE-588)4543844-4 gnd rswk-swf Molekulare Medizin (DE-588)4543844-4 s DE-604 McCulley, Michelle Verfasser aut HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016544219&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Greenwell, Pamela McCulley, Michelle Molecular therapeutics 21st century medicine Gentherapie swd Gentransfer swd Génétique moléculaire Molekulargenetik swd Thérapie génique Gene therapy Molecular genetics Gene Therapy / Popular Works Gene Therapy / Popular Works / ethics Gene Transfer Techniques / Popular Works Molecular Biology / Popular Works Molekulare Medizin (DE-588)4543844-4 gnd |
| subject_GND | (DE-588)4543844-4 |
| title | Molecular therapeutics 21st century medicine |
| title_auth | Molecular therapeutics 21st century medicine |
| title_exact_search | Molecular therapeutics 21st century medicine |
| title_exact_search_txtP | Molecular therapeutics 21st century medicine |
| title_full | Molecular therapeutics 21st century medicine Pamela Greenwell ; Michelle McCulley |
| title_fullStr | Molecular therapeutics 21st century medicine Pamela Greenwell ; Michelle McCulley |
| title_full_unstemmed | Molecular therapeutics 21st century medicine Pamela Greenwell ; Michelle McCulley |
| title_short | Molecular therapeutics |
| title_sort | molecular therapeutics 21st century medicine |
| title_sub | 21st century medicine |
| topic | Gentherapie swd Gentransfer swd Génétique moléculaire Molekulargenetik swd Thérapie génique Gene therapy Molecular genetics Gene Therapy / Popular Works Gene Therapy / Popular Works / ethics Gene Transfer Techniques / Popular Works Molecular Biology / Popular Works Molekulare Medizin (DE-588)4543844-4 gnd |
| topic_facet | Gentherapie Gentransfer Génétique moléculaire Molekulargenetik Thérapie génique Gene therapy Molecular genetics Gene Therapy / Popular Works Gene Therapy / Popular Works / ethics Gene Transfer Techniques / Popular Works Molecular Biology / Popular Works Molekulare Medizin |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016544219&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT greenwellpamela moleculartherapeutics21stcenturymedicine AT mcculleymichelle moleculartherapeutics21stcenturymedicine |